Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone


No votes yet
 
Related
ROVI recibe la opinión positiva del CHMP para Okedi® como tratamiento de la esquizofrenia
Laboratorios Farmacéuticos Rovi, a pan-European pharmaceutical company specializing and engaging in the research, development, contract...
4 min
17/12/2021
2021 Capital Markets Day presentation
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION (COMISIÓN NACIONAL DEL MERCADO DE VALORES) Madrid, 16 November 2021 In...
1 min
16/11/2021
First Nine Months 2021 Results Press Release
REVENUES Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specialized and dedicated to the...
5 min
03/11/2021